Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
50 participants
INTERVENTIONAL
2016-12-31
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
open fractures type II and III
Every patients will receive Ceftaroline in an open label, single arm
Ceftaroline
IV Ceftaroline will be given for 72 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ceftaroline
IV Ceftaroline will be given for 72 hours
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* complete an informed consent
* patients are diagnosed with a type II or III open fracture
Exclusion Criteria
* prior to enrollment: patients received 3 or more doses of antibiotic prophylaxis
* pregnant female
* inability to provide consent
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Olayemi Osiyemi MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Olayemi Osiyemi MD
President/
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olayemi Osiyemi, MD
Role: PRINCIPAL_INVESTIGATOR
Triple O Research Institute PA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Triple O Research Institute PA
West Palm Beach, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TEF-IT-40B
Identifier Type: -
Identifier Source: org_study_id